Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Can vitamin D3 supplementation reduce the time to severe asthma exacerbations in children with asthma?

Idan Bokobza, Nour El Hadi, Andrew Bush, Heidi Makrinioti
Breathe 2021 17: 210071; DOI: 10.1183/20734735.0071-2021
Idan Bokobza
1West Middlesex University Hospital, Chelsea, and Westminster Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: idanbokobza@nhs.net
Nour El Hadi
1West Middlesex University Hospital, Chelsea, and Westminster Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Bush
2Imperial Centre for Paediatrics and Child Health, Imperial College, London, UK
3National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heidi Makrinioti
1West Middlesex University Hospital, Chelsea, and Westminster Foundation Trust, London, UK
2Imperial Centre for Paediatrics and Child Health, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Vitamin D deficiency in children needs to be treated irrespective of asthma benefits. The VDKA trial showed that vitamin D supplementation in school-age asthmatic children with vitamin D insufficiency did not improve asthma control. https://bit.ly/2UF3j61

Commentary on:

Forno E, et al. Effect of Vitamin D3 supplementation on severe asthma exacerbations in children with asthma and low vitamin D levels: the VDKA randomized clinical trial. JAMA 2020; 324: 752–760.

Context

There is considerable evidence that the prevalence of asthma is increasing in industrialised countries, particularly in children and young adults [1]. Exacerbations of asthma constitute the main burden of the disease for children and their families. The majority of asthma exacerbations are triggered by respiratory viruses, most commonly rhinoviruses (RVs) [2, 3]. Host immune responses to respiratory viruses are important in asthma exacerbations. Mechanistic studies have identified immunomodulatory and anti-inflammatory roles for vitamin D [4, 5]. Figure 1 describes the actions of vitamin D on B-cells, T-cells and activated mast cells in the context of an allergen/virus-induced exacerbation of asthma. Vitamin D has also been shown to induce regulatory T-cell differentiation and interleukin (IL)-10 secretion that helps attenuate the airway smooth muscle cell hypertrophy which underlies severe asthma pathophysiology [6]. Particularly for RV, vitamin D has been shown to downregulate RV replication through induction of interferons (IFNs) and IFN-stimulated pathways [7]. Although the protective levels of vitamin D for bone health have been well described, we do not know what levels of vitamin D are needed for optimal immune responses to respiratory viral infections [8]. Vitamin D deficiency is defined as measurable levels of 25-hydroxyvitamin D below 20 ng·mL−1 and vitamin D insufficiency is defined as measurable levels of 25-hydroxyvitamin D below 30 ng·mL−1 [9], but these are based solely on bone markers.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Actions of vitamin D on B-cells, T-cells and activated mast cells in the context of an allergen/virus-induced exacerbation of asthma. Th: T-helper cell; Treg: regulatory T-cell; Ig: immunoglobulin.

There is evidence from observational cohort studies linking low 25-hydroxyvitamin D levels with asthma incidence in children [10, 11]. A systematic review of the literature on studies examining the impact of vitamin D supplementation in children with early diagnosed asthma failed to show clear positive impact [12]. Also, there is unclear evidence around the link between severity of asthma and low 25-hydroxyvitamin D levels [10]. Importantly, prior to the Vitamin D Kids Asthma (VDKA) trial [13], other studies including either preschool or school-age children had not focused only on children with low 25-hydroxyvitamin D levels or on those who are at high risk for severe asthma exacerbations (assessed by poor asthma control) [11, 14]. A recently published randomised controlled trial including younger children with vitamin D deficiency showed no positive impact of vitamin D3 supplementation on incidence of asthma exacerbations and on asthma control [15]. It is important to understand the effect of age as a cofounder in these trial results. Preschool wheeze is not asthma and all preschool children with wheeze do not have similar responses to treatments [16]. Table 1 summarises the main characteristics of randomised controlled trials in preschool and school-age children with asthma.

View this table:
  • View inline
  • View popup
Table 1

Randomised controlled trials of vitamin D3 supplementation in preschool and school-age children with asthma

In view of the lack of conclusive evidence, a research study assessing possible protective effects of vitamin D3 supplementation in children with low 25-hydroxyvitamin D levels and asthma was missing.

Methods

The VDKA study was a randomised, double-blind, placebo controlled clinical trial [13]. The primary outcome was the time to severe asthma exacerbation post vitamin D3 supplementation. The secondary outcomes were the time to viral-induced severe asthma exacerbation, the number of patients who were able to reduce the use of their preventer medication by half, and the cumulative dose of inhaled steroids required over the study period.

Recruitment took place in seven US healthcare centres. Children at high-risk for asthma exacerbation with vitamin D deficiency and/or insufficiency (age 6–16 years old) were recruited. Asthma was diagnosed by a physician at a clinic visit. Asthma diagnosis was based on a history of at least one severe asthma exacerbation that required systemic steroid treatment in the preceding year or use of any asthma medications for at least 6 months over the preceding year. A forced expiratory volume in the first second of expiration (FEV1) ≥70% of predicted was a further entry requirement. Inclusion criteria for the serum levels of 25-hydroxyvitamin D were 10 to 30 ng·mL−1 (protocol changed to 14 to 30 ng·mL−1 during the study).

The participants were randomised to receive 4000 IU of daily Vitamin D3 or placebo. Both groups received an inhaled corticosteroid (fluticasone propionate) (88 μg twice per day in children aged 6–11 years and 110 μg twice per day in children ≥12 years). Prior asthma medications were discontinued. 25-hydroxyvitamin D levels were measured at randomisation and every 16 weeks. Participants’ asthma control was assessed 24 weeks after recruitment by using the Asthma Control Test (ACT). Adherence to medications was assessed electronically and via returned pill counts.

Results

The VDKA study aimed to recruit 400 participants, however the trial recruitment was stopped early based on interim analysis due to lack of efficacy of vitamin D3 supplementation. The study recruited 192 participants equally distributed in both groups and showed that vitamin D3 supplementation did not impact on the time to a severe asthma exacerbation as compared with placebo. The mean number of days until a severe exacerbation was 240 days in the vitamin D3 group and 253 days in the placebo group with a mean difference of −13.1 days (p=0.63). The study also found no significant difference for any of the secondary outcomes.

Children who received vitamin D3 supplementation were significantly more likely to achieve a 25-hydroxyvitamin D level higher than 30 ng·mL−1 compared with the placebo group (87.2% versus 30.1%, respectively, at 48 weeks; p-value <0.001). They reached mean 25-hydroxyvitamin D levels of 49.4 ng·mL−1 (95% CI 44.9–53.9 ng·mL−1) at 48 weeks compared with 24.6 ng·mL−1 (95% CI 22.9–26.3 ng·mL−1) in the placebo group.

The authors demonstrated statistically that both groups were similar in terms of baseline characteristics including age, ethnicity, parental education, household smoking, season of enrolment, weight, and lung function parameters.

Adverse events were similar in both groups, with hospitalisations for asthma exacerbations accounting for the majority. There were no cases of hypercalcaemia or vitamin D toxicity in either group.

Commentary

It is still unclear whether vitamin D3 supplementation in children with vitamin D deficiency and asthma could impact positively on the incidence of asthma exacerbations. A Cochrane meta-analysis of the literature, only including double-blind, randomised trials in both adults and children with asthma, showed that vitamin D3 supplementation could decrease the incidence of severe asthma exacerbations from 6% to around 3%, but did not have a positive impact on asthma control [22]. Interestingly, the recruitment in the VDKA trial was paused early in view of lack of efficacy of vitamin D3 supplementation, assessed by failure to decrease incidence of severe asthma exacerbations by 16% (a high number considering previous trials [22]).

This resulted in 180 participants (92 patients in the treatment group and 88 patients in the placebo group) completing the trial with a median duration of follow-up of 332 days. Only 63 out of 180 participants (35% of the recruited patients) had serum 25-hydroxyvitamin D levels below 20 ng·mL−1. Therefore, the impact of vitamin D3 supplementation in asthmatic children with vitamin D deficiency was not assessed because of lack of statistical power. Hence the outcomes are only relevant to children with asthma and vitamin D insufficiency.

The daily dose of 4000 IU per day for vitamin D3 supplementation is higher than the dose that has been used in other clinical trials [15]. This high dose for vitamin D3 supplementation resulted in an increase of 25-hydroxyvitamin D levels in children with asthma from 22.5 ng·mL−1 to 57.2 ng·mL−1 at 16 weeks post supplementation.

Also, a total of 36 participants (37.5%) in the vitamin D3 supplementation group and 33 participants (34.4%) in the placebo group had at least one severe asthma exacerbation during the trial. Although the authors commented that this asthma exacerbation incidence is lower than expected, US emergency department activity data have reported lower numbers of asthma exacerbations within a year in children with asthma [23]. Furthermore, this study enrolled participants with moderate asthma control, as defined by good lung capacity (FEV1 more than 70% of predicted), and a mean baseline ACT score >19 [13].

The proportion of participants whose inhaled steroid dose could be reduced during the trial was not significantly different between the vitamin D3 supplementation group (28 participants) and the placebo group (29 participants). Also, there was no impact of vitamin D3 supplementation on the cumulative use of inhaled steroids during the trial. This is contrasting to evidence from the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial, where vitamin D3 supplementation had a significant effect on reducing the overall use of inhaled steroids [24]. The VIDA trial used an extra initial dose of oral vitamin D3 supplementation (100 000 IU once); however, the effect on vitamin D levels following supplementation did not differ between the VKDA and the VIDA trials and could not explain the differences in the impact on use of preventive steroids.

What is clear is that vitamin D deficiency in children needs to be treated irrespective of asthma benefits. In intervention studies, patients with vitamin D deficiency or insufficiency who receive placebo need to be carefully monitored for any vitamin D deficiency-related symptoms.

Implications for clinical practice

Currently, children diagnosed with asthma do not routinely undergo vitamin D testing. They might already be on oral vitamin D3 supplementation if diagnosed with insufficiency or deficiency. The VKDA trial showed that vitamin D3 supplementation in children with asthma and 25-hydroxyvitamin D levels less than 30 ng·mL−1 did not impact positively on asthma exacerbations nor improve asthma control. It is of note that these conclusions cannot be applied in children younger than 5 years old, who are more likely to have non-eosinophilic asthma phenotypes. Also, the results cannot inform decisions around the use of vitamin D3 in patients with vitamin D deficiency.

It is therefore important that clinical trials including younger children with vitamin D deficiency will be designed so that outcomes can inform clinical practice. It is also important that these clinical trials include ethnic groups who are at higher risk for vitamin D deficiency. Clinicians need to remember that mechanistic studies showed an effect on vitamin D treatment upon respiratory viral infection. A possible study design with an increase in the dose of oral vitamin D3 supplementation with the first symptoms of a virus-induced asthma exacerbation, might better translate the laboratory findings into clinical practice.

Footnotes

  • Conflict of interest: I. Bokobza has nothing to disclose.

  • Conflict of interest: N. El Hadi has nothing to disclose.

  • Conflict of interest: A. Bush has nothing to disclose.

  • Conflict of interest: H. Makrinioti has nothing to disclose.

  • Received April 30, 2021.
  • Accepted July 14, 2021.
  • Copyright ©ERS 2021
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Burr ML,
    2. Butland BK,
    3. King S, et al.
    Changes in asthma prevalence: two surveys 15 years apart. Arch Dis Child 1989; 64: 1452–1456. doi:10.1136/adc.64.10.1452
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Johnston SL
    . A, B, and C Rhinoviruses: New Knowledge from an Impressive Consortium. A step forward for rhinovirus vaccine efforts or a step back? Am J Respir Crit Care Med 2021; 203: 786–788. doi:10.1164/rccm.202102-0346ED
    OpenUrl
  3. ↵
    1. Lee SW,
    2. Yon DK,
    3. James CC, et al.
    Short-term effects of multiple outdoor environmental factors on risk of asthma exacerbations: Age-stratified time-series analysis. J Allergy Clin Immunol 2019; 144: 1542–1550. doi:10.1016/j.jaci.2019.08.037
    OpenUrlPubMed
  4. ↵
    1. Bleakley AS,
    2. Licciardi PV,
    3. Binks MJ
    . Vitamin D modulation of the innate immune response to paediatric respiratory pathogens associated with acute lower respiratory infections. Nutrients 2021; 13: 276. doi:10.3390/nu13010276
    OpenUrl
  5. ↵
    1. Zhao R,
    2. Zhang W,
    3. Ma C, et al.
    Immunomodulatory function of vitamin D and its role in autoimmune thyroid disease. Front Immunol 2021; 12: 574967. doi:10.3389/fimmu.2021.574967
    OpenUrl
  6. ↵
    1. Gupta A,
    2. Sjoukes A,
    3. Richards D, et al.
    Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med 2011; 184: 1342–1349. doi:10.1164/rccm.201107-1239OC
    OpenUrlCrossRefPubMed
  7. ↵
    1. Telcian AG,
    2. Zdrenghea MT,
    3. Edwards MR, et al.
    Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. Antiviral Res 2017; 137: 93–101. doi:10.1016/j.antiviral.2016.11.004
    OpenUrlPubMed
  8. ↵
    1. Zdrenghea MT,
    2. Makrinioti H,
    3. Bagacean C, et al.
    Vitamin D modulation of innate immune responses to respiratory viral infections. Rev Med Virol 2017; 27: e1909. doi:10.1002/rmv.1909
    OpenUrl
  9. ↵
    1. Amrein K,
    2. Scherkl M,
    3. Hoffmann M, et al.
    Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020; 74: 1498–1513. doi:10.1038/s41430-020-0558-y
    OpenUrlCrossRef
  10. ↵
    1. Brehm JM,
    2. Acosta-Pérez E,
    3. Klei L, et al.
    Vitamin D insufficiency and severe asthma exacerbations in Puerto Rican children. Am J Respir Crit Care Med 2012; 186: 140–146. doi:10.1164/rccm.201203-0431OC
    OpenUrlCrossRefPubMed
  11. ↵
    1. Searing DA,
    2. Zhang Y,
    3. Murphy JR, et al.
    Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol 2010; 125: 995–1000. doi:10.1016/j.jaci.2010.03.008
    OpenUrlCrossRefPubMed
  12. ↵
    1. Stefanidis C,
    2. Martineau AR,
    3. Nwokoro C, et al.
    Vitamin D for secondary prevention of acute wheeze attacks in preschool and school-age children. Thorax 2019; 74: 977–985. doi:10.1136/thoraxjnl-2019-213278
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Forno E,
    2. Bacharier LB,
    3. Phipatanakul W, et al.
    Effect of vitamin D3 supplementation on severe asthma exacerbations in children with asthma and low vitamin D levels: the VDKA randomized clinical trial. JAMA 2020; 324: 752–760. doi:10.1001/jama.2020.12384
    OpenUrlCrossRef
  14. ↵
    1. Camargo CA, Jr.,
    2. Toop L,
    3. Sluyter J, et al.
    Effect of monthly vitamin D supplementation on preventing exacerbations of asthma or chronic obstructive pulmonary disease in older adults: post hoc analysis of a randomized controlled trial. Nutrients 2021; 13: 521. doi:10.3390/nu13020521
    OpenUrl
  15. ↵
    1. Jat KR,
    2. Goel N,
    3. Gupta N, et al.
    Efficacy of vitamin D supplementation in asthmatic children with vitamin D deficiency: a randomized controlled trial (ESDAC trial). Pediatr Allergy Immunol 2021; 32: 479–488. doi:10.1111/pai.13415
    OpenUrl
  16. ↵
    1. Bush A,
    2. Grigg J,
    3. Saglani S
    . Managing wheeze in preschool children. BMJ 2014; 348: g15. doi:10.1136/bmj.g15
    OpenUrlFREE Full Text
    1. Urashima M,
    2. Segawa T,
    3. Okazaki M, et al.
    Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010; 91: 1255–1260. doi:10.3945/ajcn.2009.29094
    OpenUrlAbstract/FREE Full Text
    1. Majak P,
    2. Olszowiec-Chlebna M,
    3. Smejda K, et al.
    Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection. J Allergy Clin Immunol 2011; 127: 1294–1296. doi:10.1016/j.jaci.2010.12.016
    OpenUrlCrossRefPubMed
    1. Tachimoto H,
    2. Mezawa H,
    3. Segawa T, et al.
    Improved control of childhood asthma with low-dose, short-term vitamin D supplementation: a randomized, double-blind, placebo-controlled trial. Allergy 2016; 71: 1001–1009. doi:10.1111/all.12856
    OpenUrl
    1. Jensen ME,
    2. Mailhot G,
    3. Alos N, et al.
    Vitamin D intervention in preschoolers with viral-induced asthma (DIVA): a pilot randomised controlled trial. Trials 2016; 17: 353. doi:10.1186/s13063-016-1483-1
    OpenUrl
    1. Kerley CP,
    2. Hutchinson K,
    3. Cormican L, et al.
    Vitamin D3 for uncontrolled childhood asthma: a pilot study. Pediatr Allergy Immunol 2016; 27: 404–412. doi:10.1111/pai.12547
    OpenUrl
  17. ↵
    1. Martineau AR,
    2. Cates CJ,
    3. Urashima M, et al.
    Vitamin D for the management of asthma. Cochrane Database Syst Rev 2016; 9: CD011511.
    OpenUrlPubMed
  18. ↵
    1. Akinbami LJ,
    2. Moorman JE,
    3. Liu X
    . Asthma prevalence, health care use, and mortality: United States, 2005–2009. Natl Health Stat Report 2011; 32: 1–14.
    OpenUrl
  19. ↵
    1. Castro M,
    2. King TS,
    3. Kunselman SJ, et al.
    Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA 2014; 311: 2083–2091. doi:10.1001/jama.2014.5052
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 17 Issue 3 Table of Contents
Breathe: 17 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Can vitamin D3 supplementation reduce the time to severe asthma exacerbations in children with asthma?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Can vitamin D3 supplementation reduce the time to severe asthma exacerbations in children with asthma?
Idan Bokobza, Nour El Hadi, Andrew Bush, Heidi Makrinioti
Breathe Sep 2021, 17 (3) 210071; DOI: 10.1183/20734735.0071-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Can vitamin D3 supplementation reduce the time to severe asthma exacerbations in children with asthma?
Idan Bokobza, Nour El Hadi, Andrew Bush, Heidi Makrinioti
Breathe Sep 2021, 17 (3) 210071; DOI: 10.1183/20734735.0071-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Context
    • Methods
    • Results
    • Commentary
    • Implications for clinical practice
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Paediatric pulmonology
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Expert opinion

  • Lung cancer screening by volume CT
  • In pursuit of the primary
  • A rare complication in a case of nonsmall cell lung carcinoma
Show more Expert opinion

Journal club

  • Impact of triple therapy on mortality in COPD
  • CPAP for secondary cardiovascular prevention in OSA patients
  • Maternal vaccination during pregnancy against infant respiratory viruses
Show more Journal club

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society